EF
NTLA icon

Empowered Funds’s Intellia Therapeutics NTLA Stock Holding History

Empowered Funds’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
13,383
-8,027
-37% -$112K ﹤0.01% 1968
2026
Q1 		$274K Buy
21,410
+224
+1% +$2.85K ﹤0.01% 1867
2025
Q4 		$190K Sell
21,186
-445
-2% -$6.13K ﹤0.01% 941
2025
Q3 		$374K Buy
21,631
+754
+4% +$9.29K ﹤0.01% 1523
2025
Q2 		$196K Buy
20,877
+8,631
+70% +$70.9K ﹤0.01% 1651
2025
Q1 		$87.1K Sell
12,246
-3,603
-23% -$36.4K ﹤0.01% 1585
2024
Q4 		$185K Buy
+15,849
New +$247K ﹤0.01% 1512

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Empowered Funds's NTLA Position: Q2 2026 in Review

Empowered Funds reduced its Intellia Therapeutics (NTLA) stake by 37% in Q2 2026, selling an estimated $112K and leaving 13,383 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #1968.

Empowered Funds first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $374K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Empowered Funds held 13,383 shares of Intellia Therapeutics worth $226K as of Q2 2026.
  • Empowered Funds sold 8,027 Intellia Therapeutics shares in Q2 2026, an estimated $112K.
  • Intellia Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1968 holding.
  • Empowered Funds first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Empowered Funds's Intellia Therapeutics position peaked at $374K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.